In REDEFINE 2, which included participants with type 2 diabetes (a population that typically shows lower weight loss with any intervention), CagriSema achieved 13.7% weight loss compared to 3.4% with placebo
This mechanism has been characterised in multiple pre-clinical studies, with particular focus on tendon and ligament repair outcomes
Participants not only lost weight but also kept it off, with significant improvements in overall health
altRx GLP-1 Review 2026: Updated for the Latest FDA Compounded Semaglutide Action - Pricing, Refund Policy, and What's Changing Compounded Semaglutide and Tirzepatide Pricing from $89, How Eligibility and Self-Pay Work, and What Patients Should Verify Before Submitting Intake ALPHARETTA, Ga., May 9, 2026 (Newswire.com) - Last Updated: May 2026